STING1 and metastatic malignant neoplasm in the lymph nodes: As shown in Table 1, in the univariate analysis, 4 factors, including tumor depth (HR = 1.997, 95% CI: 1.296–3.079, P = 0.002), lymph node metastasis (HR = 2.550, 95% CI: 1.854–3.509, P < 0.001), stage (HR = 2.534, 95% CI: 1.809–3.551, P < 0.001), and STING methylation (HR = 2.720, 95% CI: 1.862–3.975, P < 0.001) were associated with an increased risk of poor OS of LUAD patients.